Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176037
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Condom, Maria | - |
dc.contributor.author | Mussetti, Alberto | - |
dc.contributor.author | Maluquer, Clara | - |
dc.contributor.author | Parody, Rocío | - |
dc.contributor.author | González Barca, Eva | - |
dc.contributor.author | Arnan, Montserrat | - |
dc.contributor.author | Albasanz Puig, Adaia | - |
dc.contributor.author | Pomares, Helena | - |
dc.contributor.author | Salas, Maria Queralt | - |
dc.contributor.author | Carro, Itziar | - |
dc.contributor.author | Peña, Marta | - |
dc.contributor.author | Clapes, Victòria | - |
dc.contributor.author | Baca Cano, Cristina | - |
dc.contributor.author | Oliveira Ramos, Ana Carla | - |
dc.contributor.author | Sanz Linares, Gabriela | - |
dc.contributor.author | Moreno González, Gabriel | - |
dc.contributor.author | Mercadal, Santiago | - |
dc.contributor.author | Boqué Genovard, Concepción | - |
dc.contributor.author | Gudiol González, Carlota | - |
dc.contributor.author | Domingo Domènech, Eva | - |
dc.contributor.author | Sureda, Anna | - |
dc.date.accessioned | 2021-04-07T07:59:40Z | - |
dc.date.available | 2021-04-07T07:59:40Z | - |
dc.date.issued | 2021-03-03 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176037 | - |
dc.description.abstract | Background: Clinical outcomes of novel coronavirus 2019 disease (COVID-19) in onco-hematological patients are unknown. When compared to non-immunocompromised patients, onco-hematological patients seem to have higher mortality rates. Aims: We describe the characteristics and outcomes of a consecutive cohort of 24 onco-hematological patients with COVID-19 during the first month of the pandemic. We also describe variations in healthcare resource utilization within our hematology department. Methods and results: Data from patients between the first month of the pandemic were retrospectively collected. Clinical and logistic data were also collected and compared with the average values from the prior 3 months of activity. Prevalence of COVID-19 in our hematological population was 0.4%. Baseline characteristics were as follows: male sex: 83%, lymphoid diseases: 46%, median age: 69 (22-82) years. Median follow-up in survivors was 14 (9-28) days and inpatient mortality rate was 46%. Average time to moderate/severe respiratory insufficiency and death were 3 (1-10) and 10 (3-18) days, respectively. Only 1 out of every 12 patients who developed moderate to severe respiratory insufficiency recovered. Upon univariate analysis, the following factors were associated with higher mortality: age ≥ 70 years (P = .01) and D-dimer ≥900 mcg/L (P = .04). With respect to indirect effects during the COVID-19 pandemic, and when compared with the prior 3 months of activity, inpatient mortality (excluding patients with COVID-19 included in the study) increased by 56%. This was associated with a more frequent use of vasoactive drugs (+300%) and advanced respiratory support (+133%) in the hematology ward. In the outpatient setting, there was a reduction in initial visits (-55%) and chemotherapy sessions (-19%). A significant increase in phone visits was reported (+581%). Conclusion: COVID-19 pandemic is associated with elevated mortality in hematological patients. Negative indirect effects are also evident within this setting. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley Periodicals LLC. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/cnr2.1358 | - |
dc.relation.ispartof | Cancer Reports, 2021 | - |
dc.relation.uri | https://doi.org/10.1002/cnr2.1358 | - |
dc.rights | cc by (c) Condom et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Oncologia | - |
dc.subject.classification | Malalties hematològiques | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Oncology | - |
dc.subject.other | Hematologic diseases | - |
dc.title | The direct and indirect effects of COVID‐19 pandemic in a real‐life hematological setting | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-03-25T07:52:51Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33656801 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
cnr2.1358.pdf | 1.41 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License